Imaging chronic active lesions in multiple sclerosis: a consensus statement

Francesca Bagnato,Pascal Sati,Christopher C Hemond,Colm Elliott,Susan A Gauthier,Daniel M Harrison,Caterina Mainero,Jiwon Oh,David Pitt,Russell T Shinohara,Seth A Smith,Bruce Trapp,Christina J Azevedo,Peter A Calabresi,Roland G Henry,Cornelia Laule,Daniel Ontaneda,William D Rooney,Nancy L Sicotte,Daniel S Reich,Martina Absinta

DOI: https://doi.org/10.1093/brain/awae013

IF: 14.5

2024-01-18

Brain

Abstract:Chronic active lesions (CAL) are an important manifestation of chronic inflammation in multiple sclerosis (MS) and have implications for non-relapsing biological progression. In recent years, the discovery of innovative magnetic resonance imaging (MRI) and PET derived biomarkers has made it possible to detect CAL, and to some extent quantify them, in the brain of persons with MS, in vivo . Paramagnetic rim lesions on susceptibility-sensitive MRI sequences, MRI-defined slowly expanding lesions on T1-weighted (T1-w) and T2-w scans, and 18-kDa translocator protein-positive lesions on PET are promising candidate biomarkers of CAL. While partially overlapping, these biomarkers do not have equivalent sensitivity and specificity to histopathological CAL. Standardization in the use of available imaging measures for CAL identification, quantification, and monitoring is lacking. To fast-forward clinical translation of CAL, the North American Imaging in Multiple Sclerosis Cooperative developed a Consensus Statement, which provides guidance for the radiological definition and measurement of CAL. The proposed manuscript presents this Consensus Statement, summarizes the multistep process leading to it, and identifies the remaining major gaps in knowledge.

neurosciences,clinical neurology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the imaging of chronic active lesions (CAL) in multiple sclerosis (MS). Specifically, the paper aims to:

1. **Identify and quantify CAL**: Detect and quantify CAL in the brains of MS patients through innovative magnetic resonance imaging (MRI) and positron emission tomography (PET) techniques. These techniques include:
- **Paramagnetic rim lesions (PRL)**: Visible on susceptibility - sensitive MRI sequences.
- **MRI - defined slowly expanding lesions (SEL)**: Visible in T1 - weighted (T1 - w) and T2 - weighted (T2 - w) scans.
- **18 - kDa translocator protein - positive lesions (TSPO - positive lesions)**: Visible in PET scans.

2. **Standardize the imaging methods of CAL**: Currently, the identification, quantification, and monitoring of CAL lack standardization. The paper proposes a consensus statement, aiming to provide guiding standards for the radiological definition and measurement of CAL to promote the clinical translation of CAL.

3. **Evaluate the sensitivity and specificity of different imaging methods**: Although PRL, SEL, and TSPO - positive lesions are considered candidate biomarkers of CAL, their correspondence with CAL and their respective sensitivities and specificities still need further research.

4. **Promote the clinical application of CAL**: Although the importance of CAL has been recognized, in daily clinical practice, the assessment of CAL has not been routinely implemented. The paper emphasizes the importance of incorporating CAL assessment into daily clinical operations and proposes some suggestions and standards.

Through these efforts, the paper hopes to accelerate the clinical translation of CAL and provide more effective patient stratification for personalized treatment and clinical trials targeting progressive biology.